Skip to main content
SpringerLink
Log in

Molecular Biology and Genetics of Chordomas

  • Chapter
Posterior Fossa Tumors in Children

Abstract

Chordomas are extra-axial, low-grade malignancies growing slowly, located anywhere from the clivus to the sacrum on the axial skeleton. Grossly they are unencapsulated, usually lobulated, pink-gray colored, invasive tumors with foci of hemorrhage and calcifications exhibiting epithelial phenotype. Histopathologically they are classified as classic chordomas, chondroid chordomas, and atypical chordomas. Classic chordomas are characterized by the presence of physaliferous cells which are large, vacuolated, mucus-containing cells with hyperchromatic, eccentric nuclei having prominent nucleoli rarely demonstrating atypia and reticulated cytoplasm due to intracellular accumulation of glycosaminoglycans, similar to the cells of notochord. The cytoplasm is eosinophilic and stains positive with the periodic acid Schiff stain. Other cell types are stellate cells and intermediate or transitional cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 349.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 349.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW (1973) Chordomas and cartilaginous tumors at the skull base. Cancer 32:410–420

    Article  CAS  PubMed  Google Scholar 

  2. Mitchell A, Scheithauer BW, Unni KK et al (1993) Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer 72:2943–2949

    Article  CAS  PubMed  Google Scholar 

  3. Richardson MS (2001) Pathology of skull base tumors. Otolaryngol Clin North Am 34:1025–1042, vii

    Article  CAS  PubMed  Google Scholar 

  4. McMaster ML, Goldstein AM, Bromley CM et al (2001) Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control 12:1–11

    Article  CAS  PubMed  Google Scholar 

  5. Schwab JH, Boland PJ, Agaram NP et al (2009) Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother 58:339–349

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Yamaguchi T, Suzuki S, Ishiiwa H, Ueda Y (2004) Intraosseous benign notochordal cell tumours: overlooked precursors of classic chordomas? Histopathology 44:597–602

    Article  CAS  PubMed  Google Scholar 

  7. Nishiguchi T, Mochizuki K, Tsujio T et al (2010) Lumbar vertebral chordoma arising from an intraosseous benign notochordal cell tumour: radiological findings and histopathological description with a good clinical outcome. Br J Radiol 83:e49–e53

    Article  CAS  PubMed  Google Scholar 

  8. Yamaguchi T, Yamato M, Saotome K (2002) First histologically confirmed case of a classic chordoma arising in a precursor benign notochordal lesion: differential diagnosis of benign and malignant notochordal lesions. Skelet Radiol 31:413–418

    Article  Google Scholar 

  9. Klingler L, Trammell R, Allan DG et al (2006) Clonality studies in sacral chordoma. Cancer Genet Cytogenet 171:68–71

    Article  CAS  PubMed  Google Scholar 

  10. Foote RF, Ablin G, Hall WW (1958) Chordoma in siblings. Calif Med 88:383–386

    PubMed Central  CAS  PubMed  Google Scholar 

  11. Kerr WA, Allen KL, Haynes DR, Sellars SL (1975) Letter: familial nasopharyngeal chordoma. S Afr Med J 49:1584

    CAS  PubMed  Google Scholar 

  12. Stepanek J, Cataldo SA, Ebersold MJ et al (1998) Familial chordoma with probable autosomal dominant inheritance. Am J Med Genet 75:335–336

    Article  CAS  PubMed  Google Scholar 

  13. Dalprà L, Malgara R, Miozzo M et al (1999) First cytogenetic study of a recurrent familial chordoma of the clivus. Int J Cancer 81:24–30

    Article  PubMed  Google Scholar 

  14. Miozzo M, Dalprà L, Riva P et al (2000) A tumor suppressor locus in familial and sporadic chordoma maps to 1p36. Int J Cancer 87:68–72

    Article  CAS  PubMed  Google Scholar 

  15. Kelley MJ, Korczak JF, Sheridan E et al (2001) Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33. Am J Hum Genet 69:454–460

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Yang XR’, Beerman M, Bergen AW et al (2005) Corroboration of a familial chordoma locus on chromosome 7q and evidence of genetic heterogeneity using single nucleotide polymorphisms (SNPs). Int J Cancer 116:487–491

    Article  CAS  Google Scholar 

  17. Weber W, Scott RJ (2005) Case report: familial gastric cancer and chordoma in the same family. Hered Cancer Clin Pract 3:81–84

    Article  PubMed Central  PubMed  Google Scholar 

  18. Bhadra AK, Casey ATH (2006) Familial chordoma. A report of two cases. J Bone Joint Surg (Br) 88:634–636

    Article  CAS  Google Scholar 

  19. Coppens JR, Ric Harnsberger H, Finn MA et al (2009) Oronasopharyngeal chordomas. Acta Neurochir (Wien) 151:901–907

    Article  Google Scholar 

  20. Yang XR, Ng D, Alcorta DA et al (2009) T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 41:1176–1178

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Probst EN, Zanella FE, Vortmeyer AO (1993) Congenital clivus chordoma. AJNR Am J Neuroradiol 14:537–539

    CAS  PubMed  Google Scholar 

  22. Goel A, Nadkarni TD, Kirtane MV (1996) Clival chordoma in an infant. J Postgrad Med 42:51–53

    CAS  PubMed  Google Scholar 

  23. Chetty R, Levin CV, Kalan MR (1991) Chordoma: a 20-year clinicopathologic review of the experience at Groote Schuur Hospital, Cape Town. J Surg Oncol 46:261–264

    Article  CAS  PubMed  Google Scholar 

  24. Scheil S, Brüderlein S, Liehr T et al (2001) Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32:203–211

    Article  CAS  PubMed  Google Scholar 

  25. Hallor KH, Staaf J, Jönsson G et al (2008) Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer 98:434–442

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Ozanne BW, Spence HJ, McGarry LC, Hennigan RF (2006) Transcription factors control invasion: AP-1 the first among equals. Oncogene 26:1–10

    Article  PubMed  Google Scholar 

  27. Vujovic S, Henderson S, Presneau N et al (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209:157–165

    Article  CAS  PubMed  Google Scholar 

  28. Shalaby AAE, Presneau N, Idowu BD et al (2009) Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Mod Pathol 22:996–1005

    Article  CAS  PubMed  Google Scholar 

  29. Diaz RJ, Guduk M, Romagnuolo R et al (2012) High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis. Neoplasia 14:788–798

    PubMed Central  CAS  PubMed  Google Scholar 

  30. Butler MG, Dahir GA, Hedges LK et al (1995) Cytogenetic, telomere, and telomerase studies in five surgically managed lumbosacral chordomas. Cancer Genet Cytogenet 85:51–57

    Article  CAS  PubMed  Google Scholar 

  31. Butler MG, Sciadini M, Hedges LK, Schwartz HS (1996) Chromosome telomere integrity of human solid neoplasms. Cancer Genet Cytogenet 86:50–53

    Article  CAS  PubMed  Google Scholar 

  32. Pallini R, Maira G, Pierconti F et al (2003) Chordoma of the skull base: predictors of tumor recurrence. J Neurosurg 98:812–822

    Article  PubMed  Google Scholar 

  33. Aue G, Muralidhar B, Schwartz HS, Butler MG (1998) Telomerase activity in skeletal sarcomas. Ann Surg Oncol 5:627–634

    Article  CAS  PubMed  Google Scholar 

  34. Lauer NK, Maier SM, Oberringer M et al (2002) Absence of telomerase activity in malignant bone tumors and soft-tissue sarcomas. Sarcoma 6:43–46

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Ricci-Vitiani L, Pierconti F, Falchetti ML et al (2006) Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Technical note. J Neurosurg 105:482–484

    Article  PubMed  Google Scholar 

  36. Eisenberg MB, Woloschak M, Sen C, Wolfe D (1997) Loss of heterozygosity in the retinoblastoma tumor suppressor gene in skull base chordomas and chondrosarcomas. Surg Neurol 47:156–160, discussion 160–1

    Article  CAS  PubMed  Google Scholar 

  37. Naka T, Boltze C, Kuester D et al (2005) Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression. Cancer 104:1255–1263

    Article  CAS  PubMed  Google Scholar 

  38. Bergh P, Kindblom LG, Gunterberg B et al (2000) Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 88:2122–2134

    Article  CAS  PubMed  Google Scholar 

  39. Kilgore S, Prayson RA (2002) Apoptotic and proliferative markers in chordomas: a study of 26 tumors. Ann Diagn Pathol 6:222–228

    Article  PubMed  Google Scholar 

  40. Toguchida J, Yamaguchi T, Ritchie B et al (1992) Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194–6199

    CAS  PubMed  Google Scholar 

  41. Riva P, Crosti F, Orzan F et al (2003) Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 107:493–497

    Article  CAS  PubMed  Google Scholar 

  42. Bayrakli F, Guney I, Kilic T et al (2007) New candidate chromosomal regions for chordoma development. Surg Neurol 68:425–430, discussion 430

    Article  PubMed  Google Scholar 

  43. Longoni M, Orzan F, Stroppi M et al (2008) Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study. Neuro Oncol 10:52–60

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Lee-Jones L, Aligianis I, Davies PA et al (2004) Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2. Genes Chromosome Cancer 41:80–85

    Article  CAS  Google Scholar 

  45. Han S, Polizzano C, Nielsen GP et al (2009) Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res 15:1940–1946

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Dobashi Y, Suzuki S, Sato E et al (2009) EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol 22:1328–1340

    Article  CAS  PubMed  Google Scholar 

  47. Yang C, Schwab JH, Schoenfeld AJ et al (2009) A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther 8:2597–2605

    Article  CAS  PubMed  Google Scholar 

  48. Yang C, Hornicek FJ, Wood KB et al (2010) Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. Spine (Phila Pa 1976) 35:1668–1675

    Article  Google Scholar 

  49. Casali PG, Messina A, Stacchiotti S et al (2004) Imatinib mesylate in chordoma. Cancer 101:2086–2097

    Article  CAS  PubMed  Google Scholar 

  50. Stacchiotti S, Marrari A, Tamborini E et al (2009) Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 20:1886–1894

    Article  CAS  PubMed  Google Scholar 

  51. Weinberger PM, Yu Z, Kowalski D et al (2005) Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 131:707–711

    Article  PubMed  Google Scholar 

  52. Burger H, den Bakker MA, Kros JM et al (2005) Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 4:1270–1274

    Article  CAS  PubMed  Google Scholar 

  53. Walter BA, Begnami M, Valera VA et al (2011) Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression. J Neurooncol 101:199–206

    Article  CAS  PubMed  Google Scholar 

  54. Naka T, Boltze C, Samii A et al (2009) Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. Histopathology 54:607–613

    Article  PubMed  Google Scholar 

  55. Naka T, Iwamoto Y, Shinohara N et al (1997) Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol 10:832–838

    CAS  PubMed  Google Scholar 

  56. Naka T, Kuester D, Boltze C et al (2008) Expression of hepatocyte growth factor and c-MET in skull base chordoma. Cancer 112:104–110

    Article  PubMed  Google Scholar 

  57. Horten BC, Montague SR (1976) In vitro characteristics of a sacrococcygeal chordoma maintained in tissue and organ culture systems. Acta Neuropathol 35:13–25

    Article  CAS  PubMed  Google Scholar 

  58. Liu X, Nielsen GP, Rosenberg AE et al (2012) Establishment and characterization of a novel chordoma cell line: CH22. J Orthop Res 30:1666–1673

    Article  CAS  PubMed  Google Scholar 

  59. DeComas AM, Penfornis P, Harris MR et al (2010) Derivation and characterization of an extra-axial chordoma cell line (EACH-1) from a scapular tumor. J Bone Joint Surg Am 92:1231–1240

    Article  PubMed  Google Scholar 

  60. Trucco MM, Awad O, Wilky BA et al (2013) A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology. PLoS ONE 8:e79950

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Burger A, Vasilyev A, Tomar R et al (2014) A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12. Dis Model Mech 7(7):907–13

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Acibadem University, School of Medicine, Istanbul, Turkey

    Mustafa Güdük M.D.

  2. Division of Pediatric Neurosurgery, Department of Neurosurgery, Acibadem University, School of Medicine, Istanbul, Turkey

    M. Memet Özek M.D.

Authors
  1. Mustafa Güdük M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Memet Özek M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mustafa Güdük M.D. .

Editor information

Editors and Affiliations

  1. Neurosurgery, Acıbadem University, Istanbul, Istanbul, Turkey

    M. Memet Özek

  2. Pediatric Neurosurgery, Santobono Children's Hospital, Naples, Napoli, Italy

    Giuseppe Cinalli

  3. Dept. Neurosurgery, Royal Childrens Hospital, Melbourne, Victoria, Australia

    Wirginia Maixner

  4. Pediatric Neurosurgery, Hopital Necker-Enfants Malades, Paris, Paris, France

    Christian Sainte-Rose

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Güdük, M., Özek, M.M. (2015). Molecular Biology and Genetics of Chordomas. In: Özek, M., Cinalli, G., Maixner, W., Sainte-Rose, C. (eds) Posterior Fossa Tumors in Children. Springer, Cham. https://doi.org/10.1007/978-3-319-11274-9_44

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-11274-9_44

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-11273-2

  • Online ISBN: 978-3-319-11274-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation